|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
|
19468690 |
2009 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We sorted human glioblastoma T98G and U87MG cells into CD133<sup>+</sup> and CD133<sup>-</sup> pools and measured apoptosis and CD133 expression levels in response to cisplatin treatment.
|
30267383 |
2018 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Results showed that the IgY-abrin immunotoxin had cytotoxic activity against CD133+ MGSCs and provides a novel approach for the immunotherapy of glioblastoma.
|
31275378 |
2019 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Variability of PROM1 expression levels in human GBM and patient-derived xenografts (PDX) - from no expression to strong, uniform expression--highlights that PROM1 may not always be associated with or restricted to cancer stem cells.
|
25184684 |
2014 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, NAMPT expression correlated with high levels of Nanog, CD133 and CIC-like cells in glioblastoma directly extracted from patients.
|
29245920 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD9 silencing in three CD133+ glioblastoma cell lines (NCH644, NCH421k and NCH660h) led to decreased cell proliferation, survival, invasion, and self-renewal ability, and altered expression of the stem-cell markers CD133, nestin and SOX2.
|
26573230 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that CD133+ glioblastoma cells presenting stem-cell properties may express pro-vascular molecules allowing them to form blood vessels de novo.
|
20375132 |
2010 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, we identified the crossreactivity of CD133 and MDR1 in a surgical specimen of GBM.
|
19832037 |
2009 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
WIP knockdown from mtp53-expressing glioblastoma and breast cancer cells (BCC) greatly reduced proliferation and growth capacity of cancer stem cell (CSC)-like cells and decreased CSC-like markers (CD133, CD44 or YAP/TAZ). mtp53 overexpression in human astrocytes enhanced their proliferative capacity in suspension culture and increased expression of CSC markers and WIP.
|
28166194 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We reported that WIP knockdown in mtp53-expressing glioblastoma greatly reduced proliferation and growth capacity of cancer stem cell (CSC)-like cells and decreased CSC-like markers, such as hyaluronic acid receptor (CD44), prominin-1 (CD133), yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ).
|
29890731 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we demonstrated that two functionally related microRNAs, miR-20a and -106a (miR-20a/106a), were capable of enhancing the invasiveness of CD133(+) glioma stem cells (GSCs) isolated from both glioblastoma cell line U87 and primary human glioma specimens.
|
24704830 |
2015 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PKD2 was also expressed in CD133-positive glioblastoma stem cells and various glioblastoma cell lines in which the kinase was found to be constitutively active.
|
21727210 |
2011 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.
|
21220328 |
2011 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In order to better understand the mechanisms regulating the tumorigenic properties of this population, we studied the role of the polycomb group member BMI1 in our patient-derived GBM BTICs and its relationship with CD133, a well-established marker of BTICs.
|
31115870 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, one recent report demonstrated that <i>LIS1</i> gene is preferentially expressed in CD133+ glioblastoma cells and may have also an important role in regulating CD133+ CSC in glioblastoma.
|
31750243 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
|
25749043 |
2015 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we characterize the expression and role of Bmi1 in primary minimally cultured human glioblastoma (GBM) patient isolates in CD133+ and CD133- sorted populations.
|
22265735 |
2012 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
More importantly, higher CD133 expression is associated with poor prognosis in glioblastoma and breast cancer patients.
|
28602756 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the current study, miR-203 expression was reduced in CD133(+) GBM-SCs derived from six human GBM biopsies.
|
27484906 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that CSC concept is more complex than it was believed before, and CD133 could not define entire stem cell population within GBM.
|
23836332 |
2014 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, our data provide first evidence that CD133(+) CSC maintain only a subset of primary glioblastomas.
|
17483311 |
2007 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Association of glial to mesenchymal transition (GMT)-related molecular with ObR expression and VM formation in glioblastoma tissues indicated that ObR-positive glioblastoma cells with GMT phenotype might be more likely to constitute VM, and co-expression of ObR and CD133 or Nestin to constitute the channel impliated that ObR-positive glioblastoma cells displayed glioblastoma stem cells (GSC) properties.
|
28938545 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
More importantly, the constructed therapeutic <sup>CD133</sup>mAb/TMAMbs have a specifically effective uptake via the CD133 transmembrane protein that is overexpressed in U251 glioblastoma cells and displayed an effective antitumor proliferation and invasive ability.
|
31573817 |
2019 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
GBM CSCs were detected with CD133/1 and CD111 antibodies after co-culture studies.
|
23737374 |
2013 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we report miRNA expression profiles of glioblastoma stem cell-containing CD133(+) cell populations.
|
21857646 |
2011 |